You are here

Notice of recommendations to prepare a document in substitution for the current Poisons Standard - New Chemical Entities (NCEs)

14 January 2020

This web publication constitutes a notice of recommendations for the scheduling of New Chemical Entities for inclusion in the Poisons Standard under section 52D(2)(b) of the Therapeutic Goods Act 1989, whereby a new Poisons Standard (including schedules containing the names or descriptions of substances or classes of substances) is prepared in substitution for the current Poisons Standard. The new Poisons Standard will come into effect on 1 February 2020.

Note

New text is shown as green, larger font, with a horizontal line above it.

1.1. Recommendation in relation to acalabrutinib

Schedule 4 - New Entry

ACALABRUTINIB.

Index - New Entry

ACALABRUTINIB

Schedule 4

Date of effect

1 February 2020

1.2. Recommendation in relation to alanylglutamine

Schedule 4 - New Entry

ALANYLGLUTAMINE.

Index - New Entry

ALANYLGLUTAMINE

Schedule 4

Date of effect

1 February 2020

1.3. Recommendation in relation to baloxavir marboxil

Schedule 4 - New Entry

BALOXAVIR MARBOXIL.

Index - New Entry

BALOXAVIR MARBOXIL

Schedule 4

Date of effect

1 February 2020

1.4. Recommendation in relation to enasidenib

Schedule 4 - New Entry

ENASIDENIB.

Index - New Entry

ENASIDENIB

Schedule 4

Date of effect

1 February 2020

1.5. Recommendation in relation to entrectinib

Schedule 4 - New Entry

ENTRECTINIB.

Index - New Entry

ENTRECTINIB

Schedule 4

Date of effect

1 February 2020

1.6. Recommendation in relation to gilteritinib

Schedule 4 - New Entry

GILTERITINIB.

Index - New Entry

GILTERITINIB

Schedule 4

Date of effect

1 February 2020

1.7. Recommendation in relation to siponimod

Schedule 4 - New Entry

SIPONIMOD.

Index - New Entry

SIPONIMOD

Schedule 4

Date of effect

1 February 2020

1.8. Recommendation in relation to sodium glycerophosphate hydrate

Schedule 4 - New Entry

SODIUM GLYCEROPHOSPHATE HYDRATE.

Index - New Entry

SODIUM GLYCEROPHOSPHATE HYDRATE

Schedule 4

Date of effect

1 February 2020

1.9. Recommendation in relation to upadacitinib

Schedule 4 - New Entry

UPADACITINIB.

Index - New Entry

UPADACITINIB

Schedule 4

Date of effect

1 February 2020

1.10. Recommendation in relation to voretigene neparvovec

Schedule 4 - New Entry

VORETIGENE NEPARVOVEC.

Index - New Entry

VORETIGENE NEPARVOVEC

Schedule 4

Date of effect

1 February 2020